Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVutisiri Veerasarnen_US
dc.contributor.authorPramook Phromratanapongseen_US
dc.contributor.authorNan Suntornpongen_US
dc.contributor.authorVicharn Lorvidhayaen_US
dc.contributor.authorVimol Sukthomyaen_US
dc.contributor.authorImjai Chitapanaruxen_US
dc.contributor.authorChanawat Tesavibulen_US
dc.contributor.authorThiti Swangsilpaen_US
dc.contributor.authorCholakiet Khorpraserten_US
dc.contributor.authorKanjana Shotelersuken_US
dc.contributor.authorYongyut Kongthanaraten_US
dc.contributor.authorApichart Panichevaluken_US
dc.contributor.authorSunanta Chiewviten_US
dc.contributor.authorPawana Pusuwanen_US
dc.contributor.authorMonreudee Aekmahachaien_US
dc.contributor.authorSamart Ratchadaraen_US
dc.contributor.authorSasitorn Sirilipocheen_US
dc.contributor.authorYuttana Saengsudaen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherPramongkutklao Hospitalen_US
dc.contributor.otherChiang Mai Universityen_US
dc.contributor.otherChulalongkorn Universityen_US
dc.contributor.otherRajavithi Hospitalen_US
dc.identifier.citationJournal of the Medical Association of Thailand. Vol.89, No.12 (2006), 2056-2067en_US
dc.description.abstractBackground: Amifostine has a potential role for salivary gland protection in head and neck cancer patients who had radiotherapy. Material and Method: Sixty-seven head and neck cancer patients were randomized to receive radiotherapy or radiotherapy plus Amifostine. The efficacy of the treatment was determined by a questionnaire evaluating dryness of mouth and the oral comfort, the RTOG/EORTC acute/late radiation morbidity scoring criteria, collection of the whole saliva and the 99mTc-pertecnetate scintigraphy of the salivary glands. Results: Amifostine significantly reduced the mean questionnaire scores from 6.49 to 3.73, the incidence of grade ≥ 2 mucositis from 75% to 36% and acute xerostomia from 82% to 39%. The salivary gland function returned to normal at a rate of 36.3% in the Amifostine group versus 9.1% in the control group. Conclusion: Amifostine is effective in reducing the incidence and severity of acute mucositis, acute and late xerostomia in head and neck cancer patients.en_US
dc.rightsMahidol Universityen_US
dc.titleEffect of amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland functionen_US
Appears in Collections:Scopus 2006-2010

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.